Preclinical News and Research

RSS

Novel DNA nanoplatform offers hope for chronic gum disease

Millions of people worldwide live with periodontitis, a chronic gum disease that can progressively destroy the tissues and bone supporting the teeth despite conventional treatment.

16 Jul 2026

Weill Cornell Medicine receives DoD grant to target triple-negative breast cancer

Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.

16 Jul 2026

Researchers rank 11 preeclampsia therapies as top candidates for further development

Researchers ranked 83 preclinical candidates for preventing or treating preeclampsia and eclampsia, identifying 11 as having high potential for further development. The analysis also revealed limited target diversity, moderate bias, inactive programs, and animal models that may not fully represent human pregnancy

15 Jul 2026

New drug candidate improves Parkinson's treatment in animal models

For many people with Parkinson's disease, the body stops moving the way it used to. A hand may tremble at rest. Muscles may stiffen.

15 Jul 2026

Self-assembling antibody drugs successfully target multiple cancer receptors

Modern anticancer medications that combine tumor-fighting drugs with proteins that specifically target cancer cells are a relatively new class of drug, often given to patients for whom standard chemotherapy has not worked.

15 Jul 2026

Targeted nanoparticles destroy tumor cells by triggering cuproptosis

A promising cancer treatment strategy called cuproptosis, which uses copper-dependent cell death to eliminate tumor cells, faces a major challenge: many approaches require adding external copper, potentially increasing toxicity beyond the tumor.

15 Jul 2026

Building the next generation of DMTA for future-ready drug discovery

Discover how the next generation of DMTA is creating a future-ready drug discovery engine through AI and automation.

From TTP plc 15 Jul 2026

Experimental gene therapy reverses fragile X symptoms in mice

A gene therapy designed to replace the missing protein that causes fragile X syndrome restored several disease-relevant traits in a mouse model, according to a new study published in Gene Therapy.

14 Jul 2026

Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing.

14 Jul 2026

Humanoid robots could take on low-risk operating room tasks before assisting surgical teams

A new perspective proposes a staged framework for introducing humanoid robots into operating rooms, beginning with laboratory testing and low-risk perioperative tasks. The authors argue that humanoids could support supplies, equipment, room turnover, and selected nursing functions, but autonomous clinical use remains premature and requires rigorous validation, governance, and human oversight.

14 Jul 2026

New wearable microneedle patch tracks medicine levels in real time

Wearable devices have transformed how people track exercise, sleep, heart rate and other vital signs.

14 Jul 2026

Poor sleep alters brain communication networks differently across adult lifespan

Have trouble sleeping? The reason may depend in part on your age. A recent study including psychology researchers from Binghamton University, State University of New York investigates how poor sleep alters brain communication across the adult lifespan, specifically examining how these changes vary by age and biological sex.

14 Jul 2026

Study reports a counterintuitive new approach to treating mesothelioma

Mesothelioma is a rare but aggressive cancer, usually caused by exposure to asbestos. Inhaled asbestos fibers become lodged in the lungs, causing inflammation that can lead to tumor formation decades later. Worldwide, about 30,000 people are diagnosed with mesothelioma each year.

14 Jul 2026

EpilepsyGTx partners with ClearPoint Neuro to support targeted delivery of lead gene therapy in epilepsy

EpilepsyGTx, a biotechnology company developing cutting-edge gene therapies to treat refractory epilepsy, and ClearPoint Neuro ("ClearPoint"), a global therapy-enabling company offering precise navigation and delivery to the brain, today announced a partnership to support the targeted delivery of EpilepsyGTx's lead gene therapy candidate, EPY201, for focal refractory epilepsy (FRE).

From EpilepsyGTx 14 Jul 2026

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.

14 Jul 2026

Combination treatment strategy uses cells' waste removal functions to dismantle multiple myeloma

New research out of VCU Massey Comprehensive Cancer Center provides promising evidence for an innovative combination treatment strategy that uses cells' waste removal functions to effectively dismantle multiple myeloma.

13 Jul 2026

Dysregulation of immune regulator NF-κB drives major human diseases

NF‑κB controls genes involved in inflammation, immunity, cell survival, and proliferation. Triggered by cytokines (TNF‑α, IL‑1β), microbial products, or cellular stress, it translocates to the nucleus and induces pro‑inflammatory mediators.

13 Jul 2026

New therapy targets Hippo pathway to fight treatment-resistant acute myeloid leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) through activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance.

13 Jul 2026

Blocking ZFP384 protein extends brain repair window after stroke

Blocking the activity of ZFP384 can prolong the brain’s endogenous repair functions after stroke, report researchers in a collaborative study.

13 Jul 2026

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

Treating glioblastoma with a class of drugs known as EGFR inhibitors made this cancer more sensitive to chemotherapy, suggests a study in preclinical models co-led by researchers at UT Southwestern Medical Center and the University of Alabama at Birmingham.

12 Jul 2026

Preclinical News and Research

Novel DNA nanoplatform offers hope for chronic gum disease

Weill Cornell Medicine receives DoD grant to target triple-negative breast cancer

Researchers rank 11 preeclampsia therapies as top candidates for further development

New drug candidate improves Parkinson's treatment in animal models

Self-assembling antibody drugs successfully target multiple cancer receptors

Targeted nanoparticles destroy tumor cells by triggering cuproptosis

Building the next generation of DMTA for future-ready drug discovery

Experimental gene therapy reverses fragile X symptoms in mice

Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Humanoid robots could take on low-risk operating room tasks before assisting surgical teams

New wearable microneedle patch tracks medicine levels in real time

Poor sleep alters brain communication networks differently across adult lifespan

Study reports a counterintuitive new approach to treating mesothelioma

EpilepsyGTx partners with ClearPoint Neuro to support targeted delivery of lead gene therapy in epilepsy

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Combination treatment strategy uses cells' waste removal functions to dismantle multiple myeloma

Dysregulation of immune regulator NF-κB drives major human diseases

New therapy targets Hippo pathway to fight treatment-resistant acute myeloid leukemia

Blocking ZFP384 protein extends brain repair window after stroke

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics